JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Omnicell Inc

Închisă

SectorSănătate

42.82 -5.54

Rezumat

Modificarea prețului

24h

Curent

Minim

41.56

Maxim

45.78

Indicatori cheie

By Trading Economics

Venit

-7.5M

-2M

Vânzări

3.4M

314M

P/E

Medie Sector

940.75

67.147

Marjă de profit

-0.645

Angajați

3,580

EBITDA

-9.8M

21M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+31.47% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-526M

1.7B

Deschiderea anterioară

48.36

Închiderea anterioară

42.82

Sentimentul știrilor

By Acuity

26%

74%

99 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Omnicell Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 23:53 UTC

Câștiguri

Naver Posts Weaker First-Quarter Earnings

29 apr. 2026, 23:41 UTC

Acțiuni populare

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr. 2026, 23:55 UTC

Câștiguri

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr. 2026, 23:54 UTC

Câștiguri

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr. 2026, 23:52 UTC

Câștiguri

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr. 2026, 23:51 UTC

Câștiguri

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr. 2026, 23:22 UTC

Câștiguri

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr. 2026, 23:22 UTC

Câștiguri

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr. 2026, 23:20 UTC

Câștiguri

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr. 2026, 23:20 UTC

Câștiguri

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Loss Narrows>000002.SZ

29 apr. 2026, 23:18 UTC

Câștiguri

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr. 2026, 23:17 UTC

Câștiguri

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr. 2026, 23:15 UTC

Câștiguri

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr. 2026, 23:15 UTC

Câștiguri

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr. 2026, 23:13 UTC

Câștiguri

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr. 2026, 23:12 UTC

Câștiguri

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr. 2026, 23:11 UTC

Câștiguri

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr. 2026, 23:11 UTC

Câștiguri

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr. 2026, 23:04 UTC

Câștiguri

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr. 2026, 23:04 UTC

Câștiguri

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparație

Modificare preț

Omnicell Inc Așteptări

Obiectiv de preț

By TipRanks

31.47% sus

Prognoză pe 12 luni

Medie 59.83 USD  31.47%

Maxim 70 USD

Minim 49 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOmnicell Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

6

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

24.23 / 30.44Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

99 / 348 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat